OBI-3424
- Generic Name
- OBI-3424
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N4O6P
- CAS Number
- 2097713-68-1
- Unique Ingredient Identifier
- X6SH5T8H76
- Background
OBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL)).
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Ascentawits Pharmaceuticals, Ltd
- Target Recruit Count
- 51
- Registration Number
- NCT06239155
- Locations
- 🇨🇳
Guangdong Qifu Hospital, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District, Nanjing, Jiangsu, China
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)
- Conditions
- Refractory T Acute Lymphoblastic LeukemiaRecurrent T Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 39
- Registration Number
- NCT04315324
- Locations
- 🇺🇸
McFarland Clinic - Trinity Cancer Center, Fort Dodge, Iowa, United States
🇺🇸North Memorial Medical Health Center, Robbinsdale, Minnesota, United States
🇺🇸Minnesota Oncology Hematology PA-Woodbury, Woodbury, Minnesota, United States
A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- OBI Pharma, Inc
- Target Recruit Count
- 68
- Registration Number
- NCT03592264
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.